NexCAR19 uses a human‑derived design, reducing the risk of severe neurological side effects compared with mouse‑derived versions.
The cost is roughly one‑tenth of comparable therapies available in Western countries, improving accessibility.
Command Hospital (Eastern Command) in Kolkata successfully administered the treatment, marking a milestone in Indian military medical care.
The approach provides a new option for patients whose blood cancers have not responded to standard therapies.
The therapy, called NexCAR19, was created through a partnership of Indian Institute of Technology Bombay, Tata Memorial Centre and the biotech start‑up ImmunoACT.
It modifies the patient’s own T‑cells to target the CD19 protein on cancer cells, offering a cheaper alternative to imported treatments.
Want to learn even more? Click here to read the full story!